Alisol A solid dispersion single-layer osmotic pump controlled release tablet and preparation method thereof

Through the design of the single-layer osmotic pump controlled release tablet of Alassium A solid dispersion, the problem of Alassium A being difficult to dissolve in water is solved, the continuous and constant release of drugs is achieved, and the bioavailability and industrial applicability of preparation is improved. .

CN119015246APending Publication Date: 2024-11-26SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310606317.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Alisma A is difficult to dissolve in water, has low oral bioavailability and short half-life, which affects its efficacy. It is difficult to effectively release existing osmotic pump tablets and achieve the expected results.

Method used

The monolayer osmotic pump controlled release tablet of Alassium A solid dispersion is adopted to improve the solubility of Alassium A through solid dispersion technology, and the drug release rate is adjusted in combination with suspension and eye promoter to prepare a constant release rate. Tablets use semi-permeable coating film and water-soluble pore-generating agent to form small pores to achieve continuous release of the drug.

Benefits of technology

The bioavailability of Alassium A was improved, and the cumulative release of drugs exceeded 90% within 12 hours, reducing the number of times patients took medication, reducing fluctuations in blood drug concentration, and the preparation method was simple and suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004250681780000021
    Figure BDA0004250681780000021
  • Figure BDA0004250681780000022
    Figure BDA0004250681780000022
  • Figure BDA0004250681780000023
    Figure BDA0004250681780000023
Patent Text Reader

Abstract

The invention discloses an alisol A solid dispersion single-layer osmotic pump controlled release tablet and a preparation method thereof. The alisol A solid dispersion single-layer osmotic pump controlled release tablet comprises a tablet core and a semipermeable coating membrane which is coated outside the tablet core and is provided with small drug release holes, the tablet core comprises the following components in percentage by weight: 8%-10% of alisol A, 45%-55% of a solid dispersion carrier, 5%-10% of a solubilizer, 15%-20% of a suspending aid, 7%-15% of a penetration enhancer, 3%-5% of an adhesive and 0.5%-2% of a lubricant; dissolving alisol A and the solid dispersion carrier material in an organic solvent, concentrating and drying to obtain solid dispersion powder; mixing the solid dispersion powder with auxiliary materials, granulating, and carrying out mold pressing to obtain a tablet core; and coating the tablet core, and punching small drug release holes in the center of a single side to obtain the alisol A solid dispersion single-layer osmotic pump controlled release tablet. The bioavailability is high, the medicine taking frequency of a patient can be reduced, the 12-hour accumulative release rate is 90% or above, industrial production is easy, and the application prospect is wide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field The invention relates to the technical field of pharmaceutical preparations, and in particular to a solid dispersion monolayer osmotic pump controlled-release tablet of an anti-atherosclerotic drug, alisol A, and a preparation method thereof. Background Art With the changes in modern diet and living habits, as well as the induction of multiple risk factors such as tobacco, obesity, diabetes and fatty liver, the incidence and mortality of atherosclerosis have been rising year by year, and the proportion of young people suffering from the disease is also quietly increasing. The formation of arterial plaques not only affects the blood supply and oxygen supply of organs in the body, but also brings a series of complications and even leads to sudden death. The proportion of deaths due to cardiovascular and cerebrovascular diseases accounts for half of the total number of deaths, which is nearly twice as high as that of tumors. Therefore, developing a drug that can effectively prevent and treat atherosclerosis is the main task at this stage. The Chinese medicine Alisma orientalis was first recorded in "Shennong's Herbal Classic". It has the effects of promoting diuresis and eliminating dampness, clearing turbidity and reducing lipids, and relieving heat. Its extracts are mainly triterpenoid compounds, among which the main active ingredient for lowering lipids is Alisma orientalis A. Modern pharmacological studies have shown that Alisma orientalis A can inhibit or reduce the occurrence and development of atherosclerosis by inhibiting lipid synthesis, accelerating cholesterol transport, and inhibiting the secretion of inflammatory factors. Chinese patent CN201210520817 discloses the use of alismatin A in the preparation of anti-atherosclerotic drugs. Animal experiments have shown that alismatin A has an inhibitory effect on ApoE - / - The atherosclerosis model induced by high-fat diet combined with carotid artery injury in mice has a significant therapeutic effect. Chinese patent CN201210473789 publicly describes the use of alisol A in the preparation of drugs for preventing and treating obesity. Animal experiments have shown that alisol A has a significant therapeutic effect on obesity models caused by high-fat diet feeding. Alismatol A belongs to the triterpenoid compound, which is insoluble in water, has low oral bioavailability and short half-life, which affects its efficacy. Oral osmotic pump preparations are the most widely used osmotic pump preparations at present. They use osmotic pressure as the main release power. After oral administration, water from the gastrointestinal tract enters the tablet core through the semipermeable membrane, dissolving the drug therein and putting it into a suspended state. The presence of permeation enhancers can ensure that there is always an osmotic pressure difference between the inside and outside of the membrane, allowing water to continuously enter the membrane, thereby pumping the drug suspension solution out from the small holes. Compared with other oral dosage forms, osmotic pump preparations have the following advantages: release of drugs at a constant rate in vivo, and the release rate is not affected by the gastrointestinal environment and pH, has better in vitro and in vivo correlation, and reduces the number of medications. Among them, the preparation process of single-layer osmotic pump controlled-release tablets is relatively simple and is more likely to be applied to industrial production. However, since alismatol A is poorly soluble in water and has a large effective dose, conventional osmotic pump tablet prescriptions are difficult to achieve the expected effect. Summary of the invention The purpose of the present invention is to provide a single-layer osmotic pump controlled-release tablet of alismatol A solid dispersion and a preparation method thereof, so as to meet the needs of clinical application. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet of the present invention comprises a tablet core and a semipermeable coating membrane with drug-releasing pores wrapped around the tablet core. The tablet core comprises the following components in weight percentage: The sum of the percentages of each component is 100%; Preferably, the core comprises the following components in weight percentage: The sum of the percentages of each component is 100%; Particularly preferably, the core comprises the following components in weight percentage: The sum of the percentages of each component is 100%; The solid dispersion carrier is selected from one or a combination of PVP K30, PVP VA64, PEG 4000, PEG 6000, poloxamer 188, dextran, and TPGS, preferably a combination of PVP VA64 and TPGS, in which the weight ratio is PVPVA64:TPGS=1:5; PVPVA64:TPGS=5:1; The solubilizing agent is selected from one or a combination of sodium dodecyl sulfate (SDS), TPGS, and Tween 80; preferably, the solubilizing agent is TPGS; The suspending agent is selected from one or a combination of carbomer, PEO N10, PEO N80, CMC-Na, sodium alginate; preferably, the suspending agent is PEON10; The penetration enhancer is selected from one or a combination of sodium chloride, mannitol, potassium chloride, and lactose. Preferably, the penetration enhancer is sodium chloride; The adhesive is selected from one or a combination of PVP K25, PVP K30, and pregelatinized starch. Preferably, the adhesive is PVP K30; The lubricant is selected from one or a combination of magnesium stearate, talcum powder, and micro-powdered silica gel. The semipermeable coating membrane is a polymer material membrane with micropores; The polymer material is selected from one or a combination of cellulose acetate, acrylic resin, and ethyl cellulose; preferably, the polymer material is cellulose acetate; The water-soluble porogen is selected from one or a combination of polyethylene glycol (PEG 1500, PEG 3350, PEG 6000), hydroxypropyl methylcellulose, and polyvinyl pyrrolidone. Preferably, the water-soluble porogen is PEG 3350. The preparation method of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets comprises the following steps: Dissolving alisol A and a solid dispersion carrier material in an organic solvent, mixing, wherein the mass concentration of the solute in the organic solvent is 4% to 5%, evaporating the organic solvent, vacuum drying, and pulverizing to obtain alisol A solid dispersion powder; The organic solvent is selected from chloroform, anhydrous ethanol, ethanol with a volume concentration of 95%, acetone, or a combination thereof. Preferably, the organic solvent is anhydrous ethanol or acetone;

[0025] The solid dispersion powder of alismatol A is mixed with other auxiliary materials except lubricant, ethanol with a volume concentration of 95% is added as a wetting agent to prepare a soft material, and the added amount is 5-7% of the weight of alismatol A, sieved and granulated, dried, granulated, weighed, lubricant is added and mixed, and single punch tablet machine is used to punch and mold with 11mm shallow concave punch to obtain the tablet core; The polymer material and the water-soluble porogen are dissolved in an organic solvent and purified water respectively, and then the two are mixed to form a coating solution; Parts by weight: The tablet core is placed in a coating pan or fluidized bed for coating, and the coating weight gain is 5% to 7% of the tablet core mass. After aging, an osmotic pump laser puncher is used to punch a drug release hole with a diameter of about 0.7 mm in the center of one side to obtain a solid dispersion monolayer osmotic pump controlled release tablet of alismatol A. The substances involved in the present invention are all commercial products. Compared with the prior art, the present invention has the following beneficial technical effects: High bioavailability: The solid dispersion monolayer osmotic pump controlled-release tablet of alisomol A of the present invention increases the solubility of alisomol A by solid dispersion technology, solves the problem that alisomol A is difficult to dissolve in water, and uses suspending agents and penetration enhancers to adjust the drug release rate. The prepared solid dispersion monolayer osmotic pump controlled-release tablet of alisomol A can continuously release at a certain rate, which can reduce the number of medications for patients and better maintain blood drug concentration. The cumulative release rate in 12 hours is above 90%, and is not affected by the gastrointestinal environment and pH. The osmotic pump preparation prepared by the method can release the drug at a constant rate within 12 hours, with a cumulative release of more than 90%, and can maintain a high blood drug concentration in the body, reduce the number of medications for patients, and reduce blood drug concentration fluctuations and gastrointestinal environmental impacts. The preparation method is simple, easy to industrialize, and has broad application prospects. The auxiliary materials are cheap and easy to obtain, and the preparation process is simple: the alisma alcohol A solid dispersion monolayer osmotic pump controlled release tablets of the present invention have cheap and easy-to-obtain auxiliary materials, and the preparation process is simple, with no special requirements for equipment, and are suitable for large-scale industrial production, and have certain application prospects. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 This is a curve chart showing the cumulative drug release rate of the solid dispersion layer osmotic pump controlled-release tablets of Alismatol A prepared in Example 1 changing with time. Figure 2 This is a curve chart showing the cumulative drug release rate of the solid dispersion layer osmotic pump controlled-release tablets of Alismatol A prepared in Example 2 changing with time. Figure 3 This is a curve chart showing the cumulative drug release rate of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets prepared in Example 3 versus time. Figure 4 This is a curve chart showing the cumulative drug release rate of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets prepared in Example 4 changing with time. Figure 5 This is a curve chart showing the cumulative drug release rate of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets prepared in Example 5 versus time. Figure 6 This is a curve chart showing the cumulative drug release rate of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets prepared in Example 6 versus time. Figure 7 This is a curve chart showing the cumulative drug release rate of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablets prepared in Example 7 versus time. Figure 8 This is the drug-time curve in beagle dogs after oral administration of the alisoma alcohol A solid dispersion monolayer osmotic pump controlled-release tablets and alisoma alcohol A suspension prepared in Example 1. Fig. 9 This is the drug-time curve in beagle dogs after oral administration of the alisoma alcohol A solid dispersion monolayer osmotic pump controlled-release tablets and alisoma alcohol A suspension prepared in Example 2. Fig.10 This is the drug-time curve in beagle dogs after oral administration of the alisoma alcohol A solid dispersion monolayer osmotic pump controlled-release tablets and alisoma alcohol A suspension prepared in Example 3. Fig.11 This is the drug-time curve in beagle dogs after oral administration of the alisoma alcohol A solid dispersion monolayer osmotic pump controlled-release tablets and alisoma alcohol A suspension prepared in Example 4. Fig.12 This is the drug release curve of Example 8 (Comparative Example). Fig.13 This is the drug release curve of Example 9 (Comparative Example). DETAILED DESCRIPTION The following are specific embodiments of the present invention, which further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these embodiments. Any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention. Example 1-Example 7 Alismatol A solid dispersion monolayer osmotic pump controlled release tablets release rate determination method: According to the first method (basket method) of dissolution and release determination in the four general rules of the 2020 edition of the Pharmacopoeia of the People's Republic of China, the in vitro cumulative release of the single-layer osmotic pump controlled-release tablets of alismatol A solid dispersion was determined. The release medium is degassed pure water (900ml) containing 0.05% SDS, the speed is 100rpm, and the temperature is (37±0.5)℃. 5ml is automatically sampled at 1, 2, 4, 6, 8, 10, and 12h, and 5ml of fresh dissolution medium at 37℃ is added immediately after each sampling. After sampling, the sample solution is filtered with a 0.45μm microporous filter membrane, and the filtrate is collected as the test solution. HPLC injection analysis is performed to calculate the cumulative release (%) of the double-layer osmotic pump controlled-release tablets of alismatol A at different sampling times.

[0053] Chromatographic conditions for content determination: Waters C 18 Reverse phase chromatography column (4.6x250nm, 5μm); mobile phase: acetonitrile-water (50:50); detection wavelength: 208nm; flow rate: 1.3ml / min; column temperature: 50℃; injection volume: 20μl. Example 1 Chip: Preparation method: Dissolve alisol A, solid dispersion carrier material and solubilizer in anhydrous ethanol, mix, evaporate to remove anhydrous ethanol to a weight concentration of 4.5%, vacuum dry, and grind to obtain alisol A solid dispersion powder; The solid dispersion powder of alismatol A is mixed with other auxiliary materials except lubricant, and a soft material made of ethanol with a wetting agent volume concentration of 95% is added, and the amount of the wetting agent added is 6% of alismatol A. The particles are sieved through a 20-mesh sieve, dried, and weighed. The lubricant is added and mixed, and a single punch tablet machine is used to punch and mold with a 11 mm shallow concave punch to obtain the tablet core; The polymer material and the water-soluble porogen are dissolved in an organic solvent and purified water respectively, and then mixed to form a coating solution. The tablet core is placed in a coating pan or a fluidized bed and coated with the coating solution. The coating weight gain is 5% of the tablet core mass. After aging, an osmotic pump laser puncher is used to punch a drug release hole with a diameter of about 0.7 mm in the center of one side to obtain a solid dispersion monolayer osmotic pump controlled release tablet of alismatol A. The weight proportions of the coating liquid components are: Example 2 Chip:

[0056] The preparation method is the same as Example 1.

[0057] Example 3

[0058] Chip The preparation method is the same as Example 1.

[0060] The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 1 is shown in Figure 1 The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 2 is shown in Figure 2 The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 3 is shown in Figure 3 By comparison, it can be seen that when PVP VA64 is selected as the carrier material, the cumulative release rate of the drug is higher and the drug release behavior is closer to the zero-order model compared with PEG 6000 and PVP K30. As can be seen from the figure, when PVP VA64, PEG 6000 and PVP K30 are used as solid dispersion carriers, the cumulative release of the drug can reach the expected level; but compared with the other two, when PVP VA64 is used, the cumulative release of the drug is higher, and the drug release behavior is closer to the zero-order kinetic equation. Figure 8 , 9 , and the pharmacokinetic curves and related data in 10, PVP VA64 was finally selected as the carrier material.

[0061] Example 4

[0062] Chip The preparation method is the same as Example 1. Example 5 Chip: The preparation method is the same as that of Example 1; The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 4 is shown in Figure 4 The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 5 is shown in Figure 5 By comparison, it can be seen that when NaCl is used as a penetration enhancer, the cumulative release of the drug in 12 hours is the highest, and the drug release behavior is closer to zero-order release. By comparison, it can be seen that when mannitol and lactose are used as penetration enhancers, the cumulative release of the drug within 12 hours is less than 90%. Compared with mannitol and lactose, when sodium chloride is used as the penetration enhancer active substance, the cumulative release of the drug within 12 hours is the highest, and the drug release behavior is closer to zero-order release. Figure 8 , Fig.11 , the preferred penetration-promoting active substance is sodium chloride. Example 6 Chip The preparation method is the same as Example 1. The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 6 is shown in Figure 6 By comparison, it can be seen that as the amount of sodium chloride in the prescription increases, the 12h cumulative release of the drug is also improved. Through Figure 1 By comparison, it can be seen that when the amount of sodium chloride in the prescription is increased, the 12-hour cumulative release of the drug is also improved. Example 7 Chip The difference between Example 7 and Example 1 is that the coating weight gain accounts for 7% of the total tablet weight. The drug release curve of the alismatol A solid dispersion monolayer osmotic pump controlled release tablets of Example 7 is shown in Figure 7 By comparison, it can be seen that when the coating film is too thick, the release rate and cumulative release of the drug will be affected, which will eventually lead to incomplete drug release and more residues. Through Figure 1 By comparison, it can be seen that when the coating weight gain increases from 5% to 7%, the drug release rate and cumulative release will be affected to varying degrees. When the coating weight gain is 7%, the cumulative release is about 80%. The reason is that the coating film is too thick, resulting in incomplete drug release and some drug residues in the preparation. Example 8 (Comparative Example) Chip: Preparation method: Mix alismatol A and other auxiliary materials except lubricant, add ethanol with a volume concentration of 95% as a wetting agent to prepare a soft material, pass through a 20-mesh sieve to granulate, dry, weigh the mass, add lubricant and mix, and use a single punch tablet machine to punch and mold with a 11 mm shallow concave punch to obtain the tablet core; The polymer material and the water-soluble porogen are dissolved in acetone and purified water respectively, wherein: The film-forming material is weighed according to the prescription amount, and the two are evenly mixed to form a coating liquid. The tablet core is placed in a coating pan for coating or fluidized bed coating. The coating weight gain is 5% of the tablet core mass. After aging, an osmotic pump laser puncher is used to punch a drug release hole with a diameter of about 0.7 mm in the center of one side to obtain a single-layer osmotic pump controlled-release tablet of alismatol A solid dispersion. The difference from Example 1 is that alismatol A is directly mixed with other excipients instead of being in the form of a solid dispersion. The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 8 is shown in Fig.12 By comparison, it can be seen that the solid dispersion of alismatol A can significantly improve the cumulative release of the preparation, and the release curve conforms to the zero-order kinetic characteristics. Example 9 (Comparative Example) Chip: Semipermeable membrane coating liquid composition: Preparation method: Dissolve alisol A and solid dispersion carrier material (PVPVA64:TGPS=5:1) in acetone, mix, evaporate to remove organic solvent, vacuum dry, and grind to obtain alisol A solid dispersion powder; The solid dispersion powder of alismatol A is mixed with other auxiliary materials except lubricant, 95% ethanol by volume is added as a wetting agent to prepare a soft material, the particles are sieved through a 20-mesh sieve, dried, weighed, the lubricant is added and mixed, and a single punch tablet machine is used to punch and mold with a 11 mm shallow concave punch to obtain the tablet core; The polymer material and the water-soluble porogen are dissolved in acetone and purified water respectively, wherein the film-forming material is weighed according to the prescription amount, and the two are evenly mixed to form a coating solution. The tablet core is placed in a coating pan for coating, and the coating weight gain is 5% of the tablet core mass. After aging, an osmotic pump laser puncher is used to punch a drug release hole with a diameter of about 0.7 mm in the center of one side to obtain a solid dispersion monolayer osmotic pump controlled release tablet of alismatol A. The difference between Example 9 and Example 1 is that the content of the pore-forming agent PEG 3350 in the semipermeable membrane coating liquid composition is reduced. The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 9 is shown in Fig.13 By comparison, it can be seen that when the porogen content is reduced, the 12h cumulative release of the osmotic pump tablets is significantly reduced. Example 10 Experimental study on oral bioavailability of alismatol A monolayer osmotic pump tablets for beagle dogs by LC-MS / MS Ordinary suspension: Accurately weigh 100 mg of alismatol A that has been pre-sieved through a 100-mesh sieve, add 10 mL of 1% CMC-Na aqueous solution, and the final concentration of alismatol A in the suspension is 5 mg / mL. Alismatol A monolayer osmotic pump tablets: Take the Alismatol A solid dispersion monolayer osmotic pump tablets prepared in Examples 1 to 4. Dosage: 10 ml of alismatol A suspension; 1 tablet of alismatol A single-layer osmotic pump tablet Drug administration and blood collection in beagle dogs This experiment used the same batch of beagles (4 dogs, 2 males and 2 females) for a two-cycle crossover experiment with a washout period of 7 days. Fasted for 12 hours before the experiment, free access to water. In the first cycle, 2 dogs were given a suspension of alismatol A, and 2 dogs were given a single-layer osmotic pump tablet of alismatol A; in the second cycle, 2 dogs (given the suspension last week) were given a single-layer osmotic pump tablet, and the other 2 dogs were given the suspension. After fasting for 12 hours, the 4 beagles were immediately gavaged with 50 ml of warm water after oral administration of tablets and suspensions. 2 ml of blood was collected from the beagles' forelimb veins at 0, 20 minutes, 40 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours, respectively. The blood was placed in a centrifuge tube containing sodium heparin and centrifuged at 8000 rpm for 5 minutes at 4°C. The plasma was collected and stored at -20°C for testing. Instruments and Equipment Ultra-high performance liquid chromatograph (Waters, USA) XEVO TQMS triple quadrupole tandem mass spectrometer (Waters, USA) Masslynx4.1 data acquisition software (Waters, USA) Analysis conditions Chromatographic column: ACQUITY BEH C18 column (100 mm x 2.1 mm, 1.7 μm); column temperature: 35 °C; flow rate: 0.3 ml / min; injection volume: 5 μl; mobile phase A: purified water containing 0.1% acetic acid; mobile phase B: acetonitrile containing 0.1% acetic acid; mobile phase gradient conditions: 0-1.5 min, 60% B; 1.5-2.0 min, 60% B-80% B; 3.0-3.5 min, 80% B; 3.5 -3.6 min, 80% B-60% B; 3.6-4.0 min, 60% B Ion source: electrospray ion source (ESI); capillary voltage: 3.0 kv; ion source temperature: 110 ° C; desolvation temperature (nitrogen) temperature: 450 ° C; flow rate: 650 L / h; cone flow rate: 300 L / h; collision gas (argon pressure): 0.275 Pa; detection mode is positive ion detection multiple reaction monitoring mode (MRM). The cone voltage, collision induced dissociation energy and centrifugation of alismatol A and internal standard budesonide are shown in the table below. The ion pairs used for quantitative analysis are m / z 473.44→383.42 (alismatol A) and m / z431.37→147.18 (budesonide). Plasma sample processing and analysis Accurately pipette 10 μl of acetonitrile and internal standard working solution into a 2.5 ml centrifuge tube, add 100 μl of beagle dog plasma sample, and vortex to mix. Add 1.4 ml of tert-butyl methyl ether, place on a vortex shaker and vortex extract for 5 minutes to fully mix, centrifuge, aspirate the upper organic phase and place in another centrifuge tube, and concentrate to dryness using a vacuum centrifuge concentrator. Redissolve in 150 μl of acetonitrile, store at 4°C, and take 10 μl of sample for analysis when injecting. Use DAS 2.1.1 pharmacokinetic software to analyze and plot the results. The results are shown in Table 1. Figure 8 . Compared with the suspension, the bioavailability of alismatol A monolayer osmotic pump controlled-release tablets increased by about 3 times, and the half-life, MRT, Tmax, etc. were all improved. Table 1 Pharmacokinetic parameters in beagle dogs in Example 1, results are expressed as mean ± SD, n = 4 Table 2 Pharmacokinetic parameters in beagle dogs in Example 2, results are expressed as mean ± SD, n = 4 Table 3 Pharmacokinetic parameters in beagle dogs in Example 3, results are expressed as mean ± SD, n = 4 Table 4 Pharmacokinetic parameters in beagle dogs in Example 4, results are expressed as mean ± SD, n = 4

Claims

1. A solid dispersion monolayer osmotic pump controlled-release tablet of alismatol A, characterized in that: It comprises a tablet core and a semi-permeable coating membrane with drug-releasing holes wrapped around the tablet core; The tablet core comprises the following components in weight percentage: The sum of the percentages of the individual components is 100%.

2. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 1, characterized in that: The core comprises the following components in weight percentage: The sum of the percentages of the individual components is 100%.

3. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 1, characterized in that: The core comprises the following components in weight percentage: The sum of the percentages of the individual components is 100%.

4. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 1, characterized in that: The solid dispersion carrier is selected from one or a combination of PVP K30, PVP VA64, PEG 4000, PEG 6000, poloxamer 188, dextran, and TPGS.

5. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 4, characterized in that: The solid dispersion carrier is preferably a composition of PVP VA64 and TPGS, with a weight ratio of PVPVA64:TPGS=1:5; PVPVA64:TPGS=5:

1.

6. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 1, characterized in that: The solubilizing agent is selected from one or a combination of sodium dodecyl sulfate (SDS), TPGS, and Tween 80; The suspending agent is selected from one or a combination of carbomer, PEO N10, PEO N80, CMC-Na, and sodium alginate; The penetration enhancer is selected from one or a combination of sodium chloride, mannitol, potassium chloride and lactose; The adhesive is selected from one or a combination of PVP K25, PVP K30, and pregelatinized starch; The lubricant is selected from one or a combination of magnesium stearate, talcum powder, and micro-powdered silica gel.

7. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to any one of claims 1 to 6, characterized in that: The semipermeable coating membrane is a polymer material membrane with micropores.

8. The alismatol A solid dispersion monolayer osmotic pump controlled-release tablet according to claim 7, characterized in that: The polymer material is selected from one or a combination of cellulose acetate, acrylic resin, and ethyl cellulose; The water-soluble porogen is selected from one or a combination of polyethylene glycol (PEG 1500, PEG 3350, PEG 6000), hydroxypropyl methylcellulose, and polyvinyl pyrrolidone.

9. The method for preparing the alismatol A solid dispersion monolayer osmotic pump controlled release tablet according to any one of claims 1 to 8, characterized in that: The following steps are involved: Dissolving alisol A and a solid dispersion carrier material in an organic solvent, mixing, evaporating the organic solvent, vacuum drying, and pulverizing to obtain alisol A solid dispersion powder; The solid dispersion powder of alismatol A is mixed with other auxiliary materials except lubricant, and ethanol with a volume concentration of 95% is added as a wetting agent to prepare a soft material, and the added amount is 5-7% of the weight of alismatol A, sieved and granulated, dried, weighed, lubricant is added and mixed, and a single punch tablet machine is used to punch and mold with a 11mm shallow concave punch to obtain the tablet core; The polymer material and the water-soluble porogen are dissolved in an organic solvent and purified water respectively, and then the two are mixed to form a coating solution; The tablet core is placed in a coating pan or fluidized bed for coating, and the coating weight gain is 5% to 7% of the tablet core mass. After aging, an osmotic pump laser puncher is used to punch a drug release hole with a diameter of about 0.7 mm in the center of one side to obtain a solid dispersion monolayer osmotic pump controlled release tablet of alismatol A.

10. The method according to claim 9, characterized in that Dissolving alisol A and a solid dispersion carrier material in an organic solvent and mixing them, wherein the mass concentration of the solute in the organic solvent is 4% to 5%; The organic solvent is selected from one or a combination of chloroform, anhydrous ethanol, 95% ethanol by volume, and acetone; The coating liquid weight parts are: